Biocon appoints Mukesh Kamath as Interim CFO, Key Managerial Personnel

Published On 2024-06-13 10:39 GMT   |   Update On 2024-06-13 10:39 GMT

Bangalore: Biocon has announced the appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer and Key Managerial Personnel of the Company with effect from June 11, 2024.

He will be heading as CFO till a new candidate is appointed by the Board for this position. 

"We would like to inform you that the Board of Directors at its meeting held, has approved the appointment of Mr. Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer and Key Managerial Personnel of the Company, pursuant to the provisions of Section 203 of the Companies Act, 2013 with effect from June 11, 2024, till the time new CFO is appointed by the Board," the Company stated in a BSE filing.
Advertisement
Mukesh Kamath is a seasoned professional with more than 27 years of financial experience. Currently, Mukesh oversees Business Finance R & D, Indirect taxation, Capex, and other finance-related functions. Since joining Biocon in 2004 as a Management Executive, he has worked across all areas of finance within the Biocon Group. Mr. Mukesh Kamath is a qualified Chartered Accountant from the Institute of Chartered Accountants of India and holds a B. Com degree from Kuvempu University. Mukesh’s journey at Biocon began as an accountant for the construction of Biocon Park, one of the company's largest expansion projects at that time. In 2009, he moved to Clinigene International Limited, a 100% subsidiary of Biocon, where he independently managed all the areas of finance. Later in 2011, he rejoined Biocon to oversee a major joint development program with Mylan, as well as all capex projects. Prior to joining Biocon, Mukesh has worked on various roles with United Breweries Limited, Infodesk Manipal Limited and Techsar Technologies Ltd.

Biocon Limited, publicly listed in 2004, is an innovation-led, global biopharmaceutical company. It has developed and commercialized novel biologics, biosimilars and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News